TRDV1: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRDV1

NCBI ID: G28518

TRDV1

Other Name(s): hDV101S1 | T cell receptor delta variable 1

TRDV1: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

TRDV1 (hDV101S1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including human immunodeficiency virus (HIV), human herpes virus (HHV), and Hepatitis B virus (HBV). TRDV1 is a key player in the host's immune response and has been shown to play a critical role in the regulation of immune cell function and tolerance.

TRDV1 is a short non-coding RNA molecule that contains 19 amino acid residues. It is expressed in a variety of tissues and cells in the body, including the liver, spleen, and lymphocytes. TRDV1 is primarily localized to the cytoplasm of the cells in which it is expressed, and its levels can vary depending on the specific cell type and the conditions of the cell.

TRDV1 has been shown to play a critical role in the regulation of immune cell function and tolerance. Studies have shown that TRDV1 can modulate the activity of immune cells, including T cells and B cells, and that it can affect the expression of key immune genes. For example, TRDV1 has been shown to inhibit the activity of the transcription factor T-cell factor (TF), which is involved in the regulation of T cell development and function.

In addition to its role in immune cell regulation, TRDV1 has also been shown to play a critical role in the regulation of cellular processes that are important for overall cellular health and longevity. For example, TRDV1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. TRDV1 has been shown to promote the apoptosis of infected or damaged cells, which can help to prevent the spread of disease and damage to the body.

TRDV1 has also been shown to play a critical role in the regulation of cellular signaling pathways that are involved in a wide range of cellular processes, including cell growth, differentiation, and inflammation. For example, TRDV1 has been shown to play a role in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of a wide range of cellular processes, including inflammation, pain, and stress.

In addition to its role in cellular signaling pathways, TRDV1 has also been shown to play a critical role in the regulation of gene expression in the liver. The liver is a key organ that is involved in the regulation of a wide range of cellular processes, including metabolism, inflammation, and detoxification. TRDV1 has been shown to play a role in the regulation of gene expression in the liver, including the regulation of the expression of enzymes involved in metabolism and detoxification.

TRDV1 has also been shown to play a critical role in the regulation of the immune response. The immune response is a critical component of the body's defense against infection and disease, and TRDV1 has been shown to play a role in the regulation of the immune response by modulating the activity of immune cells and regulating the production of antibodies.

In conclusion, TRDV1 is a non-coding RNA molecule that has been shown to play a critical role in a wide range of cellular processes in the body. Its role in immune cell regulation, cellular signaling pathways, and gene expression has been well-documented, and TRDV1 is a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of TRDV1 in the regulation of cellular processes and its potential as a drug target.

Protein Name: T Cell Receptor Delta Variable 1

Functions: V region of the variable domain of T cell receptor (TR) delta chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:28920588, PubMed:23348415). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRDV1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRDV1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets